<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">35078982</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month><Day>25</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome.</ArticleTitle><Pagination><StartPage>446</StartPage><MedlinePgn>446</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">446</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-021-27797-1</ELocationID><Abstract><AbstractText>Following acute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) a significant proportion of individuals develop prolonged symptoms, a serious condition termed post-acute coronavirus disease 2019 (COVID-19) syndrome (PACS) or long COVID. Predictors of PACS are needed. In a prospective multicentric cohort study of 215 individuals, we study COVID-19 patients during primary infection and up to one year later, compared to healthy subjects. We discover an immunoglobulin (Ig) signature, based on total IgM and IgG3 levels, which - combined with age, history of asthma bronchiale, and five symptoms during primary infection - is able to predict the risk of PACS independently of timepoint of blood sampling. We validate the score in an independent cohort of 395 individuals with COVID-19. Our results highlight the benefit of measuring Igs for the early identification of patients at high risk for PACS, which facilitates the study of targeted treatment and pathomechanisms of PACS.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cervia</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-7120-8739</Identifier><AffiliationInfo><Affiliation>Department of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zurbuchen</LastName><ForeName>Yves</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-5387-9950</Identifier><AffiliationInfo><Affiliation>Department of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taeschler</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ballouz</LastName><ForeName>Tala</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Menges</LastName><ForeName>Dominik</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-5970-1846</Identifier><AffiliationInfo><Affiliation>Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasler</LastName><ForeName>Sara</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7357-9090</Identifier><AffiliationInfo><Affiliation>Department of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adamo</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-6161-3156</Identifier><AffiliationInfo><Affiliation>Department of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raeber</LastName><ForeName>Miro E</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0003-2609-0246</Identifier><AffiliationInfo><Affiliation>Department of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xe4;chli</LastName><ForeName>Esther</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Clinic for Internal Medicine, Uster Hospital, Uster, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rudiger</LastName><ForeName>Alain</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Limmattal Hospital, Schlieren, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>St&#xfc;ssi-Helbling</LastName><ForeName>Melina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinic for Internal Medicine, City Hospital Triemli Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huber</LastName><ForeName>Lars C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Clinic for Internal Medicine, City Hospital Triemli Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nilsson</LastName><ForeName>Jakob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Held</LastName><ForeName>Ulrike</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0003-3105-5840</Identifier><AffiliationInfo><Affiliation>Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puhan</LastName><ForeName>Milo A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0003-4721-1879</Identifier><AffiliationInfo><Affiliation>Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyman</LastName><ForeName>Onur</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-8279-5545</Identifier><AffiliationInfo><Affiliation>Department of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. onur.boyman@uzh.ch.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of Zurich, Zurich, Switzerland. onur.boyman@uzh.ch.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NRP 78 Implementation Programme</GrantID><Agency>Schweizerischer Nationalfonds zur F&#xf6;rderung der Wissenschaftlichen Forschung (Swiss National Science Foundation)</Agency><Country/></Grant><Grant><GrantID>4078P0-198431</GrantID><Agency>Schweizerischer Nationalfonds zur F&#xf6;rderung der Wissenschaftlichen Forschung (Swiss National Science Foundation)</Agency><Country/></Grant><Grant><GrantID>NRP 78 Implementation Programme</GrantID><Agency>Schweizerischer Nationalfonds zur F&#xf6;rderung der Wissenschaftlichen Forschung (Swiss National Science Foundation)</Agency><Country/></Grant><Grant><GrantID>4078P0-198431</GrantID><Agency>Schweizerischer Nationalfonds zur F&#xf6;rderung der Wissenschaftlichen Forschung (Swiss National Science Foundation)</Agency><Country/></Grant><Grant><GrantID>310030-200669</GrantID><Agency>Schweizerischer Nationalfonds zur F&#xf6;rderung der Wissenschaftlichen Forschung (Swiss National Science Foundation)</Agency><Country/></Grant><Grant><GrantID>323530-191220</GrantID><Agency>Schweizerische Akademie der Medizinischen Wissenschaften (Swiss Academy of Medical Sciences)</Agency><Country/></Grant><Grant><GrantID>323530-191230</GrantID><Agency>Schweizerische Akademie der Medizinischen Wissenschaften (Swiss Academy of Medical Sciences)</Agency><Country/></Grant><Grant><GrantID>323530-177975</GrantID><Agency>Schweizerische Akademie der Medizinischen Wissenschaften (Swiss Academy of Medical Sciences)</Agency><Country/></Grant><Grant><GrantID>YTCR 32/18</GrantID><Agency>Schweizerische Akademie der Medizinischen Wissenschaften (Swiss Academy of Medical Sciences)</Agency><Country/></Grant><Grant><GrantID>YTCR 32/18</GrantID><Agency>Gottfried und Julia Bangerter-Rhyner-Stiftung (Bangerter-Stiftung)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007075">Immunoglobulin M</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003371" MajorTopicYN="N">Cough</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004417" MajorTopicYN="N">Dyspnea</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005334" MajorTopicYN="N">Fever</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007075" MajorTopicYN="N">Immunoglobulin M</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>26</Day><Hour>5</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35078982</ArticleId><ArticleId IdType="pmc">PMC8789854</ArticleId><ArticleId IdType="doi">10.1038/s41467-021-27797-1</ArticleId><ArticleId IdType="pii">10.1038/s41467-021-27797-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324:782. doi: 10.1001/jama.2020.12839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12839</ArticleId><ArticleId IdType="pubmed">32648899</ArticleId></ArticleIdList></Reference><Reference><Citation>Silvin A, et al. Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19. Cell. 2020;182:1401. doi: 10.1016/j.cell.2020.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.08.002</ArticleId><ArticleId IdType="pmc">PMC7405878</ArticleId><ArticleId IdType="pubmed">32810439</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulte-Schrepping J, et al. Severe COVID-19 is marked by a dysregulated myeloid cell compartment. Cell. 2020;182:1419. doi: 10.1016/j.cell.2020.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.08.001</ArticleId><ArticleId IdType="pmc">PMC7405822</ArticleId><ArticleId IdType="pubmed">32810438</ArticleId></ArticleIdList></Reference><Reference><Citation>Chevrier S, et al. A distinct innate immune signature marks progression from mild to severe COVID-19. Cell Rep. Med. 2021;2:100166. doi: 10.1016/j.xcrm.2020.100166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2020.100166</ArticleId><ArticleId IdType="pmc">PMC7817872</ArticleId><ArticleId IdType="pubmed">33521697</ArticleId></ArticleIdList></Reference><Reference><Citation>To KK, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect. Dis. 2020;20:565. doi: 10.1016/S1473-3099(20)30196-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30196-1</ArticleId><ArticleId IdType="pmc">PMC7158907</ArticleId><ArticleId IdType="pubmed">32213337</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervia C, et al. Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19. J. Allergy Clin. Immunol. 2021;147:545. doi: 10.1016/j.jaci.2020.10.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.10.040</ArticleId><ArticleId IdType="pmc">PMC7677074</ArticleId><ArticleId IdType="pubmed">33221383</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Melo D, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181:1036. doi: 10.1016/j.cell.2020.04.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.04.026</ArticleId><ArticleId IdType="pmc">PMC7227586</ArticleId><ArticleId IdType="pubmed">32416070</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kampen JJA, et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19) Nat. Commun. 2021;12:267. doi: 10.1038/s41467-020-20568-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-20568-4</ArticleId><ArticleId IdType="pmc">PMC7801729</ArticleId><ArticleId IdType="pubmed">33431879</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics (ONS). Prevalence of Long COVID Symptoms and COVID-19 Complicationshttps://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlifeexpectancies/datasets/prevalenceoflongcovidsymptomsandcovid19complications (2020).</Citation></Reference><Reference><Citation>National Institute for Health Research (NIHR). Living with Covid 19&#x2014;Second Reviewhttps://evidence.nihr.ac.uk/themedreview/living-with-covid19-second-review/, 10.3310/themedreview_45225 (2021).</Citation></Reference><Reference><Citation>Menges, D. et al. Burden of post-COVID-19 syndrome and implications for healthcare service planning: a Population-based Cohort Study. PLoS ONE10.1371/journal.pone.0254523 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8274847</ArticleId><ArticleId IdType="pubmed">34252157</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah, W., Hillman, T., Playford, E. D. &amp; Hishmeh, L. Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ372, (2021) 10.1136/bmj.n136.</Citation><ArticleIdList><ArticleId IdType="pubmed">33483331</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert, N. et al. COVID-19 survivors&#x2019; reports of the timing, duration, and health impacts of post-acute sequelae of SARS-CoV-2 (PASC) infection. Preprint at medRxiv10.1101/2021.03.22.21254026 (2021).</Citation></Reference><Reference><Citation>Sudre, C. H. et al. Attributes and predictors of long COVID. Nat. Med.10.1038/s41591-021-01292-y (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. COVID-19 Clinical management: living guidance. World Health Organization www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1 (2021).</Citation></Reference><Reference><Citation>Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med. Decis. Mak. 2006;26:565. doi: 10.1177/0272989X06295361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0272989X06295361</ArticleId><ArticleId IdType="pmc">PMC2577036</ArticleId><ArticleId IdType="pubmed">17099194</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramakrishnan S, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir. Med. 2021;9:763. doi: 10.1016/S2213-2600(21)00160-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00160-0</ArticleId><ArticleId IdType="pmc">PMC8040526</ArticleId><ArticleId IdType="pubmed">33844996</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheibenbogen C, et al. Tolerability and efficacy of s.c. IgG self-treatment in ME/CFS patients with IgG/IgG subclass deficiency: a Proof-of-Concept Study. J. Clin. Med. 2021;10:2420. doi: 10.3390/jcm10112420.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10112420</ArticleId><ArticleId IdType="pmc">PMC8198960</ArticleId><ArticleId IdType="pubmed">34072494</ArticleId></ArticleIdList></Reference><Reference><Citation>Snapper CM, et al. Induction of IgG3 secretion by interferon gamma: a model for T cell-independent class switching in response to T cell-independent type 2 antigens. J. Exp. Med. 1992;175:1367. doi: 10.1084/jem.175.5.1367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.175.5.1367</ArticleId><ArticleId IdType="pmc">PMC2119217</ArticleId><ArticleId IdType="pubmed">1373759</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Bon A, et al. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity. 2001;14:461. doi: 10.1016/S1074-7613(01)00126-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1074-7613(01)00126-1</ArticleId><ArticleId IdType="pubmed">11336691</ArticleId></ArticleIdList></Reference><Reference><Citation>Deenick EK, Hasbold J, Hodgkin PD. Decision criteria for resolving isotype switching conflicts by B cells. Eur. J. Immunol. 2005;35:2949. doi: 10.1002/eji.200425719.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.200425719</ArticleId><ArticleId IdType="pubmed">16180247</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjadj J, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369:718. doi: 10.1126/science.abc6027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc6027</ArticleId><ArticleId IdType="pmc">PMC7402632</ArticleId><ArticleId IdType="pubmed">32661059</ArticleId></ArticleIdList></Reference><Reference><Citation>Sprent J, King C. COVID-19 vaccine side effects: the positives about feeling bad. Sci. Immunol. 2021;6:eabj9256. doi: 10.1126/sciimmunol.abj9256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abj9256</ArticleId><ArticleId IdType="pmc">PMC9267253</ArticleId><ArticleId IdType="pubmed">34158390</ArticleId></ArticleIdList></Reference><Reference><Citation>Akdis CA, et al. Type 2 immunity in the skin and lungs. Allergy. 2020;75:1582. doi: 10.1111/all.14318.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.14318</ArticleId><ArticleId IdType="pubmed">32319104</ArticleId></ArticleIdList></Reference><Reference><Citation>Hjelholt A, Christiansen G, S&#xf8;rensen US, Birkelund S. IgG subclass profiles in normal human sera of antibodies specific to five kinds of microbial antigens. Pathog. Dis. 2013;67:206. doi: 10.1111/2049-632X.12034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/2049-632X.12034</ArticleId><ArticleId IdType="pubmed">23620184</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemos MP, et al. In men at risk of HIV infection, IgM, IgG1, IgG3, and IgA reach the human foreskin epidermis. Mucosal Immunol. 2016;9:798. doi: 10.1038/mi.2015.103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mi.2015.103</ArticleId><ArticleId IdType="pmc">PMC4848120</ArticleId><ArticleId IdType="pubmed">26509877</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedor, C. et al. Chronic COVID-19 Syndrome and Chronic Fatigue Syndrome (ME/CFS) following the first pandemic wave in Germany&#x2014;a first analysis of a prospective observational study. Preprint at medRxiv10.1101/2021.02.06.21249256 (2021).</Citation></Reference><Reference><Citation>Akbar, A. et al. Report: long-term immunological health consequences of COVID-19. Br. Soc. Immunol.www.immunology.org/sites/default/files/BSI_Briefing_Note_August_2020_FINAL.pdf (2020).</Citation></Reference><Reference><Citation>Arnold, D. et al. Are vaccines safe in patients with Long COVID? A prospective observational study. medRxiv (2021), 10.1101/2021.03.11.21253225.30.</Citation></Reference><Reference><Citation>WHO. COVID-19 Clinical Management: Interim Guidance (World Health Organization, 2021).</Citation></Reference><Reference><Citation>ARDS-Definition-Task-Force. et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307:2526.</Citation><ArticleIdList><ArticleId IdType="pubmed">22797452</ArticleId></ArticleIdList></Reference><Reference><Citation>Shann F, Mackenzie A. Comparison of rectal, axillary, and forehead temperatures. Arch. Pediatr. Adolesc. Med. 1996;150:74. doi: 10.1001/archpedi.1996.02170260078013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpedi.1996.02170260078013</ArticleId><ArticleId IdType="pubmed">8542011</ArticleId></ArticleIdList></Reference><Reference><Citation>Quer G, et al. Wearable sensor data and self-reported symptoms for COVID-19 detection. Nat. Med. 2021;27:73. doi: 10.1038/s41591-020-1123-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1123-x</ArticleId><ArticleId IdType="pubmed">33122860</ArticleId></ArticleIdList></Reference><Reference><Citation>ISRCTN registry. Zurich Coronavirus Cohort: an Observational Study to Determine Long-term Clinical Outcomes and Immune Responses After Coronavirus Infection (COVID-19), Assess the Influence of Virus Genetics, and Examine the Spread of the Coronavirus in the Population of the Canton of Zurich, Switzerland10.1186/ISRCTN14990068 (2020).</Citation></Reference><Reference><Citation>Harrel, F. E. Regression modeling strategies. hbiostathttps://hbiostat.org/doc/rms.pdf (2021).</Citation></Reference><Reference><Citation>Riley RD, et al. Minimum sample size for developing a multivariable prediction model: PART II - binary and time-to-event outcomes. Stat. Med. 2019;38:1276. doi: 10.1002/sim.7992.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.7992</ArticleId><ArticleId IdType="pmc">PMC6519266</ArticleId><ArticleId IdType="pubmed">30357870</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley RD, et al. Penalization and shrinkage methods produced unreliable clinical prediction models especially when sample size was small. J. Clin. Epidemiol. 2021;132:88. doi: 10.1016/j.jclinepi.2020.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2020.12.005</ArticleId><ArticleId IdType="pmc">PMC8026952</ArticleId><ArticleId IdType="pubmed">33307188</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg, B. et al. Long COVID in a prospective cohort of home-isolated patients. Nat. Med. 10.1038/s41591-021-01433-3 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8440190</ArticleId><ArticleId IdType="pubmed">34163090</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrell FE, Lee KL, Califf RM, Pryor DB, Rosati RA. Regression modelling strategies for improved prognostic prediction. Stat. Med. 1984;3:143. doi: 10.1002/sim.4780030207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.4780030207</ArticleId><ArticleId IdType="pubmed">6463451</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrell FE, Lee KL, Matchar DB, Reichert TA. Regression models for prognostic prediction: advantages, problems, and suggested solutions. Cancer Treat. Rep. 1985;69:1071.</Citation><ArticleIdList><ArticleId IdType="pubmed">4042087</ArticleId></ArticleIdList></Reference><Reference><Citation>Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis II. Accuracy and precision of regression estimates. J. Clin. Epidemiol. 1995;48:1503. doi: 10.1016/0895-4356(95)00048-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0895-4356(95)00048-8</ArticleId><ArticleId IdType="pubmed">8543964</ArticleId></ArticleIdList></Reference><Reference><Citation>Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J. Clin. Epidemiol. 1996;49:1373. doi: 10.1016/S0895-4356(96)00236-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0895-4356(96)00236-3</ArticleId><ArticleId IdType="pubmed">8970487</ArticleId></ArticleIdList></Reference><Reference><Citation>Vittinghoff E, McCulloch CE. Relaxing the Rule of Ten events per variable in logistic and Cox regression. Am. J. Epidemiol. 2007;165:710. doi: 10.1093/aje/kwk052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwk052</ArticleId><ArticleId IdType="pubmed">17182981</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Calster B, McLernon DJ, van Smeden M, Wynants L, Steyerberg EW. Calibration: the Achilles heel of predictive analytics. BMC Med. 2019;17:230. doi: 10.1186/s12916-019-1466-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-019-1466-7</ArticleId><ArticleId IdType="pmc">PMC6912996</ArticleId><ArticleId IdType="pubmed">31842878</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf6;bel M, et al. Polymorphism in COMT is associated with IgG3 subclass level and susceptibility to infection in patients with chronic fatigue syndrome. J. Transl. Med. 2015;13:264. doi: 10.1186/s12967-015-0628-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-015-0628-4</ArticleId><ArticleId IdType="pmc">PMC4536662</ArticleId><ArticleId IdType="pubmed">26272340</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunkler D, Sauerbrei W, Heinze G. Global, parameterwise and joint shrinkage factor estimation. J. Stat. Softw. 2016;69:1. doi: 10.18637/jss.v069.i08.</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v069.i08</ArticleId></ArticleIdList></Reference><Reference><Citation>Held U, et al. Prognostic function to estimate the probability of meaningful clinical improvement after surgery&#x2014;results of a prospective multicenter observational cohort study on patients with lumbar spinal stenosis. PLoS ONE. 2018;13:e0207126. doi: 10.1371/journal.pone.0207126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0207126</ArticleId><ArticleId IdType="pmc">PMC6224088</ArticleId><ArticleId IdType="pubmed">30408081</ArticleId></ArticleIdList></Reference><Reference><Citation>Robin X, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinforma. 2011;12:77. doi: 10.1186/1471-2105-12-77.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-12-77</ArticleId><ArticleId IdType="pmc">PMC3068975</ArticleId><ArticleId IdType="pubmed">21414208</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiegelhalter DJ. Probabilistic prediction in patient management and clinical trials. Stat. Med. 1986;5:421. doi: 10.1002/sim.4780050506.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.4780050506</ArticleId><ArticleId IdType="pubmed">3786996</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015;350:g7594. doi: 10.1136/bmj.g7594.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.g7594</ArticleId><ArticleId IdType="pubmed">25569120</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Elm E, et al. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806. doi: 10.1136/bmj.39335.541782.AD.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.39335.541782.AD</ArticleId><ArticleId IdType="pmc">PMC2034723</ArticleId><ArticleId IdType="pubmed">17947786</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>